Enolase represents a metabolic checkpoint controlling the differential exhaustion programmes of hepatitis virus-specific CD8
alpha beta T cells
chronic viral hepatitis
hepatitis B
hepatitis C
immunology in hepatology
Journal
Gut
ISSN: 1468-3288
Titre abrégé: Gut
Pays: England
ID NLM: 2985108R
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
19
09
2022
accepted:
20
06
2023
medline:
15
9
2023
pubmed:
5
8
2023
entrez:
4
8
2023
Statut:
ppublish
Résumé
Exhausted T cells with limited effector function are enriched in chronic hepatitis B and C virus (HBV and HCV) infection. Metabolic regulation contributes to exhaustion, but it remains unclear how metabolism relates to different exhaustion states, is impacted by antiviral therapy, and if metabolic checkpoints regulate dysfunction. Metabolic state, exhaustion and transcriptome of virus-specific CD8 HBV-specific (core Metabolism of HBV-specific and HCV-specific T cells is strongly connected to their exhaustion severity. Our results highlight enolase as metabolic regulator of severely exhausted T cells. They connect differential bioenergetic fitness with distinct exhaustion subtypes and varying liver disease, with implications for therapeutic strategies.
Identifiants
pubmed: 37541771
pii: gutjnl-2022-328734
doi: 10.1136/gutjnl-2022-328734
pmc: PMC10511960
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1971-1984Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 100326/Z/12/Z
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Nat Immunol. 2021 Feb;22(2):229-239
pubmed: 33398179
J Hepatol. 2019 Nov;71(5):889-899
pubmed: 31295532
Immunity. 2016 Aug 16;45(2):358-73
pubmed: 27496729
Front Immunol. 2020 Aug 21;11:1906
pubmed: 32973789
Nat Immunol. 2021 Nov;22(11):1465
pubmed: 34588688
Sci Immunol. 2019 Jan 25;4(31):
pubmed: 30683669
Nat Immunol. 2020 Dec;21(12):1540-1551
pubmed: 33020660
Nat Commun. 2020 Jan 30;11(1):604
pubmed: 32001678
Nat Immunol. 2013 Jun;14(6):603-10
pubmed: 23644506
J Hepatol. 2014 Dec;61(6):1212-9
pubmed: 25016223
J Immunol. 2009 Jun 1;182(11):6697-708
pubmed: 19454664
Cell Rep. 2018 Feb 6;22(6):1509-1521
pubmed: 29425506
PLoS Pathog. 2010 Jun 10;6(6):e1000947
pubmed: 20548953
Viruses. 2021 Nov 13;13(11):
pubmed: 34835079
Nat Med. 2017 Mar;23(3):327-336
pubmed: 28165481
Immunity. 2018 May 15;48(5):1029-1045.e5
pubmed: 29768164
Cell. 2015 Sep 10;162(6):1229-41
pubmed: 26321679
Nat Commun. 2017 May 03;8:15050
pubmed: 28466857
Nat Immunol. 2015 Nov;16(11):1174-84
pubmed: 26414764
Nat Immunol. 2021 Aug;22(8):1020-1029
pubmed: 34312547
J Hepatol. 2021 Apr;74(4):783-793
pubmed: 33188902
Gut. 2019 May;68(5):905-915
pubmed: 30622109
Cell Rep. 2016 Aug 2;16(5):1243-1252
pubmed: 27452473
Nat Immunol. 2021 Feb;22(2):205-215
pubmed: 33398183
J Virol. 2007 Apr;81(8):4215-25
pubmed: 17287266
Immunity. 2016 Aug 16;45(2):415-27
pubmed: 27533016
Cell. 2015 Sep 10;162(6):1217-28
pubmed: 26321681
Nat Immunol. 2020 Sep;21(9):1022-1033
pubmed: 32661364
J Exp Med. 2000 Apr 17;191(8):1269-80
pubmed: 10770795
Cell. 2013 Jun 6;153(6):1239-51
pubmed: 23746840
Immunity. 2017 Oct 17;47(4):648-663.e8
pubmed: 29045899
Nat Immunol. 2013 Oct;14(10):1064-72
pubmed: 23955661